Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Transcript
What are you most looking forward to at the 2022 American Academy of Dermatology Annual Meeting?
I'm looking forward to a lot of things at AAD 2022. First of all, I'm looking forward to seeing my colleagues in person and catching up. And I'm also looking forward to really getting educated on the latest data in medical, pediatric, and cosmetic dermatology.
What can attendees expect to learn at AAD 2022?
The meeting is going to be very comprehensive, with updates in all areas of dermatology. I personally will be chairing the acne and rosacea symposium and I'll begin giving an update on what's new in topical therapy. I'll be giving some updates on what's new in acne and rosacea in general. I'll also be talking about some of the latest breakthroughs in topical therapy for psoriasis and, in one interesting session, I'll be talking about the challenges of conducting clinical trials, and specifically the challenge of patient recruiting.
What are some of the big issues in dermatology that you hope to see addressed?
There are a lot of issues in dermatology right now and Academy leadership has so much on their plates, but I think they've been doing a really good job in tackling some of our main issues. Some of these include scope of practice battles, the cost of both treating and not treating our patients, the 2022 changes in MIPS [Merit-based Incentive Payment System] and MACRA [Medicare Access and CHIP Reauthorization Act], and also helping us to restore faith in iPLEDGE [Risk Evaluation and Mitigation Strategy program]. We're also making a major push for DEI [diversity, equity, and inclusion].
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More